Anil Singhal
About
Anil Singhal is a scholar working on Hematology, Molecular Biology and Radiology, Nuclear Medicine and Imaging.
According to data from OpenAlex, Anil Singhal has authored 81 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Hematology, 34 papers in Molecular Biology and 31 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Anil Singhal's work include Multiple Myeloma Research and Treatments (34 papers), Monoclonal and Polyclonal Antibodies Research (31 papers) and Glycosylation and Glycoproteins Research (20 papers). Anil Singhal is often cited by papers focused on Multiple Myeloma Research and Treatments (34 papers), Monoclonal and Polyclonal Antibodies Research (31 papers) and Glycosylation and Glycoproteins Research (20 papers). Anil Singhal collaborates with scholars based in United States, France and Canada. Anil Singhal's co-authors include Sen‐itiroh Hakomori, Edward Nudelman, James C. Paulson, M. Laurie Phillips, F C Gaeta, Tatsushi Toyokuni, Margaret J. Polley, Elizabeth A. Wayner, S Hakomori and Ann Mohrbacher and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of the American Chemical Society.
In The Last Decade
Anil Singhal
81 papers receiving 4.4k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Anil Singhal United States | 28 | 2.8k | 1.4k | 1.3k | 1.1k | 970 | 81 | 4.5k | ||
| Jack Henkin United States | 42 | 2.5k 0.9× | 881 0.6× | 1.3k 1.0× | 429 0.4× | 218 0.2× | 111 | 4.8k | ||
| Richard E. Galardy United States | 29 | 1.6k 0.6× | 592 0.4× | 779 0.6× | 617 0.5× | 200 0.2× | 67 | 4.0k | ||
| Linda K. Jolliffe United States | 31 | 1.5k 0.5× | 619 0.4× | 780 0.6× | 959 0.8× | 815 0.8× | 60 | 3.7k | ||
| M. Laurie Phillips United States | 21 | 1.7k 0.6× | 366 0.3× | 224 0.2× | 1.1k 1.0× | 494 0.5× | 47 | 3.3k | ||
| Hiroaki Kodama Japan | 32 | 2.3k 0.8× | 418 0.3× | 1.0k 0.8× | 803 0.7× | 107 0.1× | 110 | 4.1k | ||
| Laura G. Corral United States | 36 | 2.9k 1.0× | 2.8k 2.0× | 1.8k 1.4× | 1.4k 1.3× | 143 0.1× | 61 | 6.0k | ||
| B Furie United States | 36 | 1.6k 0.6× | 2.6k 1.9× | 345 0.3× | 862 0.8× | 466 0.5× | 59 | 5.4k | ||
| Mario Del Rosso Italy | 40 | 2.2k 0.8× | 509 0.4× | 816 0.6× | 576 0.5× | 89 0.1× | 145 | 4.1k | ||
| William E. Fogler United States | 38 | 2.0k 0.7× | 216 0.2× | 1.1k 0.8× | 1.4k 1.3× | 357 0.4× | 105 | 3.9k | ||
| Karen E. Pollok United States | 38 | 2.7k 1.0× | 392 0.3× | 1.7k 1.3× | 1.6k 1.4× | 172 0.2× | 142 | 5.6k |
Countries citing papers authored by Anil Singhal
Since
Specialization
Citations
This map shows the geographic impact of Anil Singhal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anil Singhal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anil Singhal more than expected).
Fields of papers citing papers by Anil Singhal
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Anil Singhal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anil Singhal. The network helps show where Anil Singhal may publish in the future.
Co-authorship network of co-authors of Anil Singhal
This figure shows the co-authorship network connecting the top 25 collaborators of Anil Singhal. A scholar is included among the top collaborators of Anil Singhal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anil Singhal. Anil Singhal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Vij, Ravi, Rajneesh Nath, Daniel Afar, et al.. (2020). First-in-Human Phase I Study of ABBV-838, an Antibody–Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma. Clinical Cancer Research. 26(10). 2308–2317.
2.
Jakubowiak, Andrzej, Massimo Offidani, Brigitte Pegourié, et al.. (2016). Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. Blood. 127(23). 2833–2840.
3.
Richardson, Paul G., Sundar Jagannath, Philippe Moreau, et al.. (2015). Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study. The Lancet Haematology. 2(12). e516–e527.
4.
Lonial, Sagar, Meletios Α. Dimopoulos, Antonio Palumbo, et al.. (2015). ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 33(15_suppl). 8508–8508.
5.
Singhal, Anil, et al.. (2012). Superior Dislocation of the Patella: Case Report and Review of the Literature. Journal of Emergency Medicine. 44(2). 478–480.
6.
Lonial, Sagar, Paul G. Richardson, Philippe Moreau, et al.. (2012). ELOQUENT-2: A phase III, randomized, open-label trial of lenalidomide/dexamethasone (Len/Dex) with or without elotuzumab (Elo) in relapsed or refractory multiple myeloma (RR MM) (CA204-004).. Journal of Clinical Oncology. 30(15_suppl). TPS8112–TPS8112.
7.
Lam, Elaine T., S. Gail Eckhardt, Wells A. Messersmith, et al.. (2011). Abstract C18: A phase I study of enavatuzumab (PDL192, ABT-361), a first-in-class human monoclonal antibody targeting TWEAK (tumor necrosis factor-like inducer of apoptosis) receptor, in patients (Pts) with advanced solid tumors.. Molecular Cancer Therapeutics. 10(11_Supplement). C18–C18.
8.
Lonial, Sagar, Ravi Vij, Jean‐Luc Harousseau, et al.. (2010). Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma: A phase I/II study.. Journal of Clinical Oncology. 28(15_suppl). 8020–8020.
9.
Jakubowiak, Andrzej, Jack W. Singer, David S. Siegel, et al.. (2010). Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase I study.. Journal of Clinical Oncology. 28(15_suppl). 8003–8003.
10.
Jakubowiak, Andrzej, William Bensinger, David S. Siegel, et al.. (2009). Phase 1/2 Study of Elotuzumab in Combination with Bortezomib in Patients with Multiple Myeloma with One to Three Prior Therapies: Interim Results.. Blood. 114(22). 3876–3876.
11.
Gupta, Ravi, Anil Singhal, Deepak Goel, Rakesh K. Srivastava, & Sunil Mittal. (2008). Charles Bonnet Syndrome: Two Case Reports. Journal of Neuropsychiatry. 20(3). 377–378.
12.
Zonder, Jeffrey A., Seema Singhal, William Bensinger, et al.. (2008). Phase I Study of Elotuzumab (HuLuc63) in Phase I Study of Elotuzumab (HuLuc63) in Relapsed/Refractory Multiple Myeloma. Blood. 112(11). 2773–2773.
13.
Lustig, Robert A., Thomas J. Vogl, David Fromm, et al.. (2003). A multicenter Phase I safety study of intratumoral photoactivation of talaporfin sodium in patients with refractory solid tumors. Cancer. 98(8). 1767–1771.
14.
Zhang, Shengle, Carlos Cordon‐Cardo, Victor E. Reuter, et al.. (1997). Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. International Journal of Cancer. 73(1). 50–56.
15.
Ogata, Shunji, et al.. (1995). Tumor-associated sialylated antigens are constitutively expressed in normal human colonic mucosa.. PubMed. 55(9). 1869–74.
16.
Toyokuni, Tatsushi, Sen‐itiroh Hakomori, & Anil Singhal. (1994). Synthetic carbohydrate vaccines: Synthesis and immunogenicity of Tn antigen conjugates. Bioorganic & Medicinal Chemistry. 2(11). 1119–1132.
17.
Polley, Margaret J., M. Laurie Phillips, Elizabeth A. Wayner, et al.. (1991). CD62 and endothelial cell-leukocyte adhesion molecule 1 (ELAM-1) recognize the same carbohydrate ligand, sialyl-Lewis x.. Proceedings of the National Academy of Sciences. 88(14). 6224–6228.
18.
Singhal, Anil & Sen‐itiroh Hakomori. (1990). Molecular changes in carbohydrate antigens associated with cancer. BioEssays. 12(5). 223–230.
19.
Otaka, Michiro, Anil Singhal, & Sen‐itiroh Hakomori. (1989). Antibody-mediated targeting of differentiation inducers to tumor cells: Inhibition of colonic cancer cell growth in vitro and in vivo a preliminary note. Biochemical and Biophysical Research Communications. 158(1). 202–208.
20.
Singhal, Anil, Bertram I. Cohen, E.H. Mosbach, et al.. (1984). Prevention of cholesterol-induced gallstones by hyodeoxycholic acid in the prairie dog.. Journal of Lipid Research. 25(6). 539–549.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Jack Henkin Breakdown of academic impact, for papers by Richard E. Galardy Breakdown of academic impact, for papers by Linda K. Jolliffe Breakdown of academic impact, for papers by M. Laurie Phillips Breakdown of academic impact, for papers by Hiroaki Kodama Breakdown of academic impact, for papers by Laura G. Corral Breakdown of academic impact, for papers by B Furie Breakdown of academic impact, for papers by Mario Del Rosso Breakdown of academic impact, for papers by William E. Fogler Breakdown of academic impact, for papers by Karen E. Pollok